Developing a deep, sustainable pipeline of novel neurobehavioral therapeutics
We have built a growing pipeline of investigational therapeutics. We have internal discovery capabilities and expect to grow our pipeline both organically and through partnerships.
BTRX-335140 (a selective antagonist for kappa opioid receptor): We have completed a single ascending dose and multiple ascending dose Phase 1 study in healthy volunteers in which BTRX-335140 exhibited favorable pharmacokinetics and was well tolerated. Target receptor occupancy studies are underway with results expected in the second half of 2019. The first Phase 2 study for this program is expected to start in 2020.
BTRX-323511 (a selective antagonist for the vasopressin 1a receptor): We are conducting Investigational New Drug (IND)-enabling studies for social-emotional disorders such as autism spectrum disorder (ASD), and expect to file an IND in early 2020.
- Phase 1
- Phase 2
- Phase 3